Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OrbiMed Advisors LLC

This article was originally published in Start Up

Executive Summary

Specialized funds permit an investment team to make use of expertise and contacts developed within a specific industry, but can often leave investors with no place to go when an entire sector goes south. Such is not the case with OrbiMed Advisors, however. While almost entirely focused on the pharmaceutical and biotech industries, OrbiMed's philosophy of investing along a continuum of drug discovery companies globally, from "two guys in a lab with a dream, to Pfizer," and on both the long and short sides of the market, has permitted it to profit during both market upturns and downdrafts.

Topics

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC090463

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel